JP2024526149A5 - - Google Patents

Info

Publication number
JP2024526149A5
JP2024526149A5 JP2023578776A JP2023578776A JP2024526149A5 JP 2024526149 A5 JP2024526149 A5 JP 2024526149A5 JP 2023578776 A JP2023578776 A JP 2023578776A JP 2023578776 A JP2023578776 A JP 2023578776A JP 2024526149 A5 JP2024526149 A5 JP 2024526149A5
Authority
JP
Japan
Prior art keywords
capsule
delivery system
hpmc
active substance
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526149A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034683 external-priority patent/WO2022271922A1/en
Publication of JP2024526149A publication Critical patent/JP2024526149A/ja
Publication of JP2024526149A5 publication Critical patent/JP2024526149A5/ja
Pending legal-status Critical Current

Links

JP2023578776A 2021-06-24 2022-06-23 消化管への活性物質の投与を制御する方法 Pending JP2024526149A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163214438P 2021-06-24 2021-06-24
US63/214,438 2021-06-24
PCT/US2022/034683 WO2022271922A1 (en) 2021-06-24 2022-06-23 Method to control administration of active substance to the digestive tract

Publications (2)

Publication Number Publication Date
JP2024526149A JP2024526149A (ja) 2024-07-17
JP2024526149A5 true JP2024526149A5 (cg-RX-API-DMAC7.html) 2025-07-16

Family

ID=84544830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578776A Pending JP2024526149A (ja) 2021-06-24 2022-06-23 消化管への活性物質の投与を制御する方法

Country Status (8)

Country Link
US (1) US20240285699A1 (cg-RX-API-DMAC7.html)
EP (1) EP4340819A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526149A (cg-RX-API-DMAC7.html)
CN (1) CN117479929A (cg-RX-API-DMAC7.html)
AU (1) AU2022299196A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023027371A2 (cg-RX-API-DMAC7.html)
CA (1) CA3223905A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022271922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116270523B (zh) * 2023-05-15 2023-08-08 四川厌氧生物科技有限责任公司 一种耐酸的口服双层胶囊及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667167C (en) * 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
BR112012006651B1 (pt) * 2009-09-24 2021-11-03 Capsugel Belgium Nv Cápsula farmacêutica dura resistente a ácido e composição aquosa compreendendo goma de gelano e hpmc
DE102010022174A1 (de) * 2010-05-12 2011-11-17 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Darreichungsformen für Cineol
US9907755B2 (en) * 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
EP3028694B1 (en) * 2014-12-02 2017-07-12 Capsugel Belgium NV Dosage form articles for delayed release
EP3882259B1 (en) * 2015-05-13 2026-01-28 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
EP4480495A3 (en) * 2017-07-10 2025-06-18 Gel Cap Technologies, LLC Dual release dosage form capsule and methods, devices and systems for making same
US20190388344A1 (en) * 2018-06-22 2019-12-26 Probiotech Llc Method to Improve The Health Of The Microbiome In A Human Gastrointestinal System and Multi-Chamber Probiotic Delivery Products Therefor
US20200038215A1 (en) * 2018-08-01 2020-02-06 Ethicon, Inc. Transient implantable device to control absorption of nutrients
US12144834B2 (en) * 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
CA3117956A1 (en) * 2018-10-30 2020-05-07 Vitabolus Inc. Oral delivery of therapeutic mammalian cells
MX2022004515A (es) * 2019-10-16 2022-07-12 Capsugel Belgium Nv Metodo y composicion para aumentar la sintesis de proteinas musculares.

Similar Documents

Publication Publication Date Title
JP7208982B2 (ja) システアミン感受性障害の治療方法
CN104379138B (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
JP2022137225A (ja) システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
FI85439B (fi) Foerfarande foer framstaellning av ett laekemedelspreparat som doseras oralt och moejliggoer en kontrollerad frigoerelse.
RU2120798C1 (ru) Твердая фармацевтическая композиция для перорального введения
US11944707B2 (en) Dual release dosage form capsule and methods, devices and systems for making same
CA3013541A1 (en) Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN102802612A (zh) 含有5-氨基酮戊酸的固态组合物
ES3036967T3 (en) Delayed release deferiprone tablets and methods of using the same
JPH09503782A (ja) ピコサルフェート剤形
JP2010530868A (ja) デュロキセチン製剤
CN1141937C (zh) 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物
ES2605650T3 (es) Formulación farmacéutica que contiene fosfatidilcolina para el tratamiento de la colitis ulcerativa
FI3706724T3 (fi) Suun kautta otettavia rifamysiini sv -koostumuksia
CN1976685B (zh) 口服抗微生物药物组合物
CN1261273A (zh) 舍曲林的缓释剂型
JP7554807B2 (ja) 消化障害の予防および/または処置用の医薬組成物およびそれを製造する方法、並びにそれを含む医薬製品
EA200700158A1 (ru) Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой
CN120112280A (zh) 用于口服递送的组合物
CN110475547A (zh) 治疗多发性硬化症的组合物和方法
CN1972689A (zh) 河豚毒素的固体口服制剂
CN105250237A (zh) 用于制备药物传递的纳/微米气泡的医药组成物
JPS63198625A (ja) アズモレン剤形
JP2000327569A (ja) 腸内環境改善剤
CN102106842B (zh) 一种盐酸左氧氟沙星微丸胶囊及其制备方法